#crispr — Public Fediverse posts

https://www.europesays.com/at/170358/ Gentherapie und CRISPR gegen Herzinsuffizienz: ESC zeigt Fortschritte 2026 #Aav #Amyloidose #AT #Austria #Crispr #Diagnostik #Geneditierung #Gentherapie #Gesundheit #Health #Herzinsuffizienz #Immunreaktion #Kardiomyopathie #KlinischeStudie #Langzeit #Österreich #Sicherheit #Vektor #Zulassung

Hace ya algún tiempo grabé este #podcast sobre #xenotrasplantes para @elconfidencial que ahora vela luz y que os invito a escuchar. Versa sobre el uso de órganos de cerdos editados genéticamente con #CRISPR en personas, los primeros éxitos de esta técnica.
https://www.elconfidencial.com/salud/2026-05-20/cuando-llevaras-pulmon-cerdo_4351575/

DNA-guided CRISPR system targets RNA and expands Cas12 beyond gene editing

A DNA-guided CRISPR platform could make RNA detection and control more stable, scalable, and precise, op…
#NewsBeep #News #Science #AU #Australia #Biotechnology #Cancer #Cell #CRISPR #Diagnostic #Diagnostics #dna #Enzyme #Fluorescence #Gene #Genetic #Hepatitis #hepatitisC #Laboratory #PalindromicRepeats #protein #research #RibonucleicAcid #RNA #Technology #therapy #Transcription #virus
https://www.newsbeep.com/au/680023/

DNA-guided CRISPR system targets RNA and expands Cas12 beyond gene editing

A DNA-guided CRISPR platform could make RNA detection and control more stable, scalable, and precise, op…
#NewsBeep #News #Science #AU #Australia #Biotechnology #Cancer #Cell #CRISPR #Diagnostic #Diagnostics #dna #Enzyme #Fluorescence #Gene #Genetic #Hepatitis #hepatitisC #Laboratory #PalindromicRepeats #protein #research #RibonucleicAcid #RNA #Technology #therapy #Transcription #virus
https://www.newsbeep.com/au/680023/

https://www.europesays.com/ie/491719/ DNA-guided CRISPR system targets RNA and expands Cas12 beyond gene editing #Biotechnology #cancer #Cell #CRISPR #Diagnostic #Diagnostics #DNA #Éire #Enzyme #Fluorescence #Gene #Genetic #Hepatitis #HepatitisC #IE #Ireland #Laboratory #PalindromicRepeats #Protein #Research #RibonucleicAcid #RNA #Science #Technology #therapy #Transcription #virus

https://www.europesays.com/ie/486082/ New CRISPR breakthrough promises more affordable disease diagnostics #Biotechnology #Cell #CRISPR #Diagnostics #DNA #Éire #Genetic #IE #Ireland #Research #RNA #Science #Technology

David Liu (BROAD) publica en Science Translational Medicine una nueva estrategia de terapia génica basada en editores de bases (#CRISPR de segunda generación) sobre un modelo de ratón del síndrome de #Dravet con una mutación en el gen #Scn1a
https://drive.google.com/file/d/12rcxews05DxkmmD-hasC-0Ogg9RDXRdc/view?pli=1

David Liu (BROAD) publica en Science Translational Medicine una nueva estrategia de terapia génica basada en editores de bases (#CRISPR de segunda generación) sobre un modelo de ratón del síndrome de #Dravet con una mutación en el gen #Scn1a
https://drive.google.com/file/d/12rcxews05DxkmmD-hasC-0Ogg9RDXRdc/view?pli=1

David Liu (BROAD) publica en Science Translational Medicine una nueva estrategia de terapia génica basada en editores de bases (#CRISPR de segunda generación) sobre un modelo de ratón del síndrome de #Dravet con una mutación en el gen #Scn1a
https://drive.google.com/file/d/12rcxews05DxkmmD-hasC-0Ogg9RDXRdc/view?pli=1

David Liu (BROAD) publica en Science Translational Medicine una nueva estrategia de terapia génica basada en editores de bases (#CRISPR de segunda generación) sobre un modelo de ratón del síndrome de #Dravet con una mutación en el gen #Scn1a
https://drive.google.com/file/d/12rcxews05DxkmmD-hasC-0Ogg9RDXRdc/view?pli=1

Colossal Biosciences Is Making Jurassic Park Look Like a Pitch Deck

Dear Cherubs, Dallas has apparently decided extinction is just a product category. Colossal Biosciences is now a billionaire-level biotech spectacle, with the company saying its latest Series C brought total funding to $615 million and ABC News reporting a roster of celebrity backers that includes Tom Brady, Tiger Woods, Paris Hilton and Peter Jackson. Dallas Innovates also reported that the CIA’s venture arm, In-Q-Tel, invested in Colossal back in 2022.

The result is a company that sounds like it was brainstormed by a film studio, a venture fund and a very committed science teacher. Colossal says it is working on de-extinction projects tied to the woolly mammoth, dodo, thylacine and dire wolf, using gene editing, synthetic biology and related conservation tools. So no, this is not literally Jurassic Park; it is more like Jurassic Park after legal review and a lot of grant money.

THE TEA, BUT WITH MICROPIPETTES

In April, Reuters reported that Colossal announced three genetically engineered wolf pups and called them the world’s first successfully “de-extincted” animals, while outside experts were more cautious and described them as genetically modified gray wolves with added dire-wolf traits. ABC News said Colossal edited gray wolf cells at multiple sites and noted the two species are about 99.5% genetically identical, which is a very impressive number and also a reminder that biology is rude and complicated.

That is the key detail the movie version never pauses for: the company is not dusting off a frozen dinosaur and pressing play. It is using ancient DNA, gene editing and surrogate biology to create something that resembles an extinct species closely enough to trigger headlines, debates and a healthy amount of side-eye. The label “de-extincted” is doing a lot of heavy lifting here.

WHY THE MONEY FLOWS

The money makes more sense when you look at the technology stack. Dallas Innovates reported that In-Q-Tel said its interest in Colossal was “less about the mammoths and more about the capability,” while Colossal’s own materials say the work could scale CRISPR, synthetic biology, artificial wombs and genomic preservation platforms. In other words, the extinct-animal angle is the headline; the platform is the business.

Colossal has also built a pop-culture-friendly halo around the science. Its advisory board page lists Tom Brady and George R.R. Martin among its cultural advisors, which is exactly the kind of sentence that makes the internet stop scrolling for a second. That is the trick here: make de-extinction feel part science, part blockbuster, part meme, and suddenly the cap table looks almost inevitable.

The hot take is simple: this is not a cartoonish clone factory, and it is not pure hype either. It is a very expensive attempt to push gene editing, cloning-adjacent methods and reproductive tech into territory that could one day matter for conservation as much as spectacle. The dinosaurs are still fiction, but the lab bills are extremely real.

Sources list
ABC News — https://abcnews.go.com/US/dire-wolf-revived-biotech-companys-de-extinction-process/story?id=120558562
Reuters — https://www.reuters.com/science/us-company-resurrects-extinct-dire-wolf-or-some-version-it-2025-04-08/
Dallas Innovates — https://dallasinnovates.com/mammoth-interest-the-cia-invests-in-dallas-based-colossal-biosciences/
Colossal Biosciences — https://colossal.com/colossal-secures-200m-to-accelerate-de-extinction-and-genomic-innovation/
Colossal Biosciences — https://colossal.com/advisors/
Wikimedia Commons (Laboratory.jpg) — https://commons.wikimedia.org/wiki/File:Laboratory.jpg

Colossal Biosciences Is Making Jurassic Park Look Like a Pitch Deck

Dear Cherubs, Dallas has apparently decided extinction is just a product category. Colossal Biosciences is now a billionaire-level biotech spectacle, with the company saying its latest Series C brought total funding to $615 million and ABC News reporting a roster of celebrity backers that includes Tom Brady, Tiger Woods, Paris Hilton and Peter Jackson. Dallas Innovates also reported that the CIA’s venture arm, In-Q-Tel, invested in Colossal back in 2022.

The result is a company that sounds like it was brainstormed by a film studio, a venture fund and a very committed science teacher. Colossal says it is working on de-extinction projects tied to the woolly mammoth, dodo, thylacine and dire wolf, using gene editing, synthetic biology and related conservation tools. So no, this is not literally Jurassic Park; it is more like Jurassic Park after legal review and a lot of grant money.

THE TEA, BUT WITH MICROPIPETTES

In April, Reuters reported that Colossal announced three genetically engineered wolf pups and called them the world’s first successfully “de-extincted” animals, while outside experts were more cautious and described them as genetically modified gray wolves with added dire-wolf traits. ABC News said Colossal edited gray wolf cells at multiple sites and noted the two species are about 99.5% genetically identical, which is a very impressive number and also a reminder that biology is rude and complicated.

That is the key detail the movie version never pauses for: the company is not dusting off a frozen dinosaur and pressing play. It is using ancient DNA, gene editing and surrogate biology to create something that resembles an extinct species closely enough to trigger headlines, debates and a healthy amount of side-eye. The label “de-extincted” is doing a lot of heavy lifting here.

WHY THE MONEY FLOWS

The money makes more sense when you look at the technology stack. Dallas Innovates reported that In-Q-Tel said its interest in Colossal was “less about the mammoths and more about the capability,” while Colossal’s own materials say the work could scale CRISPR, synthetic biology, artificial wombs and genomic preservation platforms. In other words, the extinct-animal angle is the headline; the platform is the business.

Colossal has also built a pop-culture-friendly halo around the science. Its advisory board page lists Tom Brady and George R.R. Martin among its cultural advisors, which is exactly the kind of sentence that makes the internet stop scrolling for a second. That is the trick here: make de-extinction feel part science, part blockbuster, part meme, and suddenly the cap table looks almost inevitable.

The hot take is simple: this is not a cartoonish clone factory, and it is not pure hype either. It is a very expensive attempt to push gene editing, cloning-adjacent methods and reproductive tech into territory that could one day matter for conservation as much as spectacle. The dinosaurs are still fiction, but the lab bills are extremely real.

Sources list
ABC News — https://abcnews.go.com/US/dire-wolf-revived-biotech-companys-de-extinction-process/story?id=120558562
Reuters — https://www.reuters.com/science/us-company-resurrects-extinct-dire-wolf-or-some-version-it-2025-04-08/
Dallas Innovates — https://dallasinnovates.com/mammoth-interest-the-cia-invests-in-dallas-based-colossal-biosciences/
Colossal Biosciences — https://colossal.com/colossal-secures-200m-to-accelerate-de-extinction-and-genomic-innovation/
Colossal Biosciences — https://colossal.com/advisors/
Wikimedia Commons (Laboratory.jpg) — https://commons.wikimedia.org/wiki/File:Laboratory.jpg

Colossal Biosciences Is Making Jurassic Park Look Like a Pitch Deck

Dear Cherubs, Dallas has apparently decided extinction is just a product category. Colossal Biosciences is now a billionaire-level biotech spectacle, with the company saying its latest Series C brought total funding to $615 million and ABC News reporting a roster of celebrity backers that includes Tom Brady, Tiger Woods, Paris Hilton and Peter Jackson. Dallas Innovates also reported that the CIA’s venture arm, In-Q-Tel, invested in Colossal back in 2022.

The result is a company that sounds like it was brainstormed by a film studio, a venture fund and a very committed science teacher. Colossal says it is working on de-extinction projects tied to the woolly mammoth, dodo, thylacine and dire wolf, using gene editing, synthetic biology and related conservation tools. So no, this is not literally Jurassic Park; it is more like Jurassic Park after legal review and a lot of grant money.

THE TEA, BUT WITH MICROPIPETTES

In April, Reuters reported that Colossal announced three genetically engineered wolf pups and called them the world’s first successfully “de-extincted” animals, while outside experts were more cautious and described them as genetically modified gray wolves with added dire-wolf traits. ABC News said Colossal edited gray wolf cells at multiple sites and noted the two species are about 99.5% genetically identical, which is a very impressive number and also a reminder that biology is rude and complicated.

That is the key detail the movie version never pauses for: the company is not dusting off a frozen dinosaur and pressing play. It is using ancient DNA, gene editing and surrogate biology to create something that resembles an extinct species closely enough to trigger headlines, debates and a healthy amount of side-eye. The label “de-extincted” is doing a lot of heavy lifting here.

WHY THE MONEY FLOWS

The money makes more sense when you look at the technology stack. Dallas Innovates reported that In-Q-Tel said its interest in Colossal was “less about the mammoths and more about the capability,” while Colossal’s own materials say the work could scale CRISPR, synthetic biology, artificial wombs and genomic preservation platforms. In other words, the extinct-animal angle is the headline; the platform is the business.

Colossal has also built a pop-culture-friendly halo around the science. Its advisory board page lists Tom Brady and George R.R. Martin among its cultural advisors, which is exactly the kind of sentence that makes the internet stop scrolling for a second. That is the trick here: make de-extinction feel part science, part blockbuster, part meme, and suddenly the cap table looks almost inevitable.

The hot take is simple: this is not a cartoonish clone factory, and it is not pure hype either. It is a very expensive attempt to push gene editing, cloning-adjacent methods and reproductive tech into territory that could one day matter for conservation as much as spectacle. The dinosaurs are still fiction, but the lab bills are extremely real.

Sources list
ABC News — https://abcnews.go.com/US/dire-wolf-revived-biotech-companys-de-extinction-process/story?id=120558562
Reuters — https://www.reuters.com/science/us-company-resurrects-extinct-dire-wolf-or-some-version-it-2025-04-08/
Dallas Innovates — https://dallasinnovates.com/mammoth-interest-the-cia-invests-in-dallas-based-colossal-biosciences/
Colossal Biosciences — https://colossal.com/colossal-secures-200m-to-accelerate-de-extinction-and-genomic-innovation/
Colossal Biosciences — https://colossal.com/advisors/
Wikimedia Commons (Laboratory.jpg) — https://commons.wikimedia.org/wiki/File:Laboratory.jpg

Colossal Biosciences Is Making Jurassic Park Look Like a Pitch Deck

Dear Cherubs, Dallas has apparently decided extinction is just a product category. Colossal Biosciences is now a billionaire-level biotech spectacle, with the company saying its latest Series C brought total funding to $615 million and ABC News reporting a roster of celebrity backers that includes Tom Brady, Tiger Woods, Paris Hilton and Peter Jackson. Dallas Innovates also reported that the CIA’s venture arm, In-Q-Tel, invested in Colossal back in 2022.

The result is a company that sounds like it was brainstormed by a film studio, a venture fund and a very committed science teacher. Colossal says it is working on de-extinction projects tied to the woolly mammoth, dodo, thylacine and dire wolf, using gene editing, synthetic biology and related conservation tools. So no, this is not literally Jurassic Park; it is more like Jurassic Park after legal review and a lot of grant money.

THE TEA, BUT WITH MICROPIPETTES

In April, Reuters reported that Colossal announced three genetically engineered wolf pups and called them the world’s first successfully “de-extincted” animals, while outside experts were more cautious and described them as genetically modified gray wolves with added dire-wolf traits. ABC News said Colossal edited gray wolf cells at multiple sites and noted the two species are about 99.5% genetically identical, which is a very impressive number and also a reminder that biology is rude and complicated.

That is the key detail the movie version never pauses for: the company is not dusting off a frozen dinosaur and pressing play. It is using ancient DNA, gene editing and surrogate biology to create something that resembles an extinct species closely enough to trigger headlines, debates and a healthy amount of side-eye. The label “de-extincted” is doing a lot of heavy lifting here.

WHY THE MONEY FLOWS

The money makes more sense when you look at the technology stack. Dallas Innovates reported that In-Q-Tel said its interest in Colossal was “less about the mammoths and more about the capability,” while Colossal’s own materials say the work could scale CRISPR, synthetic biology, artificial wombs and genomic preservation platforms. In other words, the extinct-animal angle is the headline; the platform is the business.

Colossal has also built a pop-culture-friendly halo around the science. Its advisory board page lists Tom Brady and George R.R. Martin among its cultural advisors, which is exactly the kind of sentence that makes the internet stop scrolling for a second. That is the trick here: make de-extinction feel part science, part blockbuster, part meme, and suddenly the cap table looks almost inevitable.

The hot take is simple: this is not a cartoonish clone factory, and it is not pure hype either. It is a very expensive attempt to push gene editing, cloning-adjacent methods and reproductive tech into territory that could one day matter for conservation as much as spectacle. The dinosaurs are still fiction, but the lab bills are extremely real.

Sources list
ABC News — https://abcnews.go.com/US/dire-wolf-revived-biotech-companys-de-extinction-process/story?id=120558562
Reuters — https://www.reuters.com/science/us-company-resurrects-extinct-dire-wolf-or-some-version-it-2025-04-08/
Dallas Innovates — https://dallasinnovates.com/mammoth-interest-the-cia-invests-in-dallas-based-colossal-biosciences/
Colossal Biosciences — https://colossal.com/colossal-secures-200m-to-accelerate-de-extinction-and-genomic-innovation/
Colossal Biosciences — https://colossal.com/advisors/
Wikimedia Commons (Laboratory.jpg) — https://commons.wikimedia.org/wiki/File:Laboratory.jpg

Colossal Biosciences Is Making Jurassic Park Look Like a Pitch Deck

Dear Cherubs, Dallas has apparently decided extinction is just a product category. Colossal Biosciences is now a billionaire-level biotech spectacle, with the company saying its latest Series C brought total funding to $615 million and ABC News reporting a roster of celebrity backers that includes Tom Brady, Tiger Woods, Paris Hilton and Peter Jackson. Dallas Innovates also reported that the CIA’s venture arm, In-Q-Tel, invested in Colossal back in 2022.

The result is a company that sounds like it was brainstormed by a film studio, a venture fund and a very committed science teacher. Colossal says it is working on de-extinction projects tied to the woolly mammoth, dodo, thylacine and dire wolf, using gene editing, synthetic biology and related conservation tools. So no, this is not literally Jurassic Park; it is more like Jurassic Park after legal review and a lot of grant money.

THE TEA, BUT WITH MICROPIPETTES

In April, Reuters reported that Colossal announced three genetically engineered wolf pups and called them the world’s first successfully “de-extincted” animals, while outside experts were more cautious and described them as genetically modified gray wolves with added dire-wolf traits. ABC News said Colossal edited gray wolf cells at multiple sites and noted the two species are about 99.5% genetically identical, which is a very impressive number and also a reminder that biology is rude and complicated.

That is the key detail the movie version never pauses for: the company is not dusting off a frozen dinosaur and pressing play. It is using ancient DNA, gene editing and surrogate biology to create something that resembles an extinct species closely enough to trigger headlines, debates and a healthy amount of side-eye. The label “de-extincted” is doing a lot of heavy lifting here.

WHY THE MONEY FLOWS

The money makes more sense when you look at the technology stack. Dallas Innovates reported that In-Q-Tel said its interest in Colossal was “less about the mammoths and more about the capability,” while Colossal’s own materials say the work could scale CRISPR, synthetic biology, artificial wombs and genomic preservation platforms. In other words, the extinct-animal angle is the headline; the platform is the business.

Colossal has also built a pop-culture-friendly halo around the science. Its advisory board page lists Tom Brady and George R.R. Martin among its cultural advisors, which is exactly the kind of sentence that makes the internet stop scrolling for a second. That is the trick here: make de-extinction feel part science, part blockbuster, part meme, and suddenly the cap table looks almost inevitable.

The hot take is simple: this is not a cartoonish clone factory, and it is not pure hype either. It is a very expensive attempt to push gene editing, cloning-adjacent methods and reproductive tech into territory that could one day matter for conservation as much as spectacle. The dinosaurs are still fiction, but the lab bills are extremely real.

Sources list
ABC News — https://abcnews.go.com/US/dire-wolf-revived-biotech-companys-de-extinction-process/story?id=120558562
Reuters — https://www.reuters.com/science/us-company-resurrects-extinct-dire-wolf-or-some-version-it-2025-04-08/
Dallas Innovates — https://dallasinnovates.com/mammoth-interest-the-cia-invests-in-dallas-based-colossal-biosciences/
Colossal Biosciences — https://colossal.com/colossal-secures-200m-to-accelerate-de-extinction-and-genomic-innovation/
Colossal Biosciences — https://colossal.com/advisors/
Wikimedia Commons (Laboratory.jpg) — https://commons.wikimedia.org/wiki/File:Laboratory.jpg

https://www.europesays.com/es/546837/ Hallan CRISPR capaz de eliminar tumores sin dañar tejido sano #cáncer #CélulasCancerígenas #CienciaYTecnología #crispr #ES #España #Health #Salud #Spain #TejidoSano

L'epatite E uccide ogni anno 44 mila persone nel mondo. Non esiste un farmaco specifico: vent'anni di ricerca, e ancora terapia di supporto. Ora un gruppo della Ruhr-Universität di Bochum ha mostrato che il sistema CRISPR/Cas13d, quello che taglia l'RNA invece del DNA, riesce a spegnere il virus nelle cellule umane.

È una fase di laboratorio, capiamoci: non ancora un farmaco. Ma di novità serie su questo virus se ne vedono poche. Benvenuta ricerca.

https://www.futuroprossimo.it/2026/05/epatite-e-nel-mirino-di-crispr-il-virus-si-spegne-in-laboratorio

#epatite #CRISPR

L'epatite E uccide ogni anno 44 mila persone nel mondo. Non esiste un farmaco specifico: vent'anni di ricerca, e ancora terapia di supporto. Ora un gruppo della Ruhr-Universität di Bochum ha mostrato che il sistema CRISPR/Cas13d, quello che taglia l'RNA invece del DNA, riesce a spegnere il virus nelle cellule umane.

È una fase di laboratorio, capiamoci: non ancora un farmaco. Ma di novità serie su questo virus se ne vedono poche. Benvenuta ricerca.

https://www.futuroprossimo.it/2026/05/epatite-e-nel-mirino-di-crispr-il-virus-si-spegne-in-laboratorio

#epatite #CRISPR

L'epatite E uccide ogni anno 44 mila persone nel mondo. Non esiste un farmaco specifico: vent'anni di ricerca, e ancora terapia di supporto. Ora un gruppo della Ruhr-Universität di Bochum ha mostrato che il sistema CRISPR/Cas13d, quello che taglia l'RNA invece del DNA, riesce a spegnere il virus nelle cellule umane.

È una fase di laboratorio, capiamoci: non ancora un farmaco. Ma di novità serie su questo virus se ne vedono poche. Benvenuta ricerca.

https://www.futuroprossimo.it/2026/05/epatite-e-nel-mirino-di-crispr-il-virus-si-spegne-in-laboratorio

#epatite #CRISPR

L'epatite E uccide ogni anno 44 mila persone nel mondo. Non esiste un farmaco specifico: vent'anni di ricerca, e ancora terapia di supporto. Ora un gruppo della Ruhr-Universität di Bochum ha mostrato che il sistema CRISPR/Cas13d, quello che taglia l'RNA invece del DNA, riesce a spegnere il virus nelle cellule umane.

È una fase di laboratorio, capiamoci: non ancora un farmaco. Ma di novità serie su questo virus se ne vedono poche. Benvenuta ricerca.

https://www.futuroprossimo.it/2026/05/epatite-e-nel-mirino-di-crispr-il-virus-si-spegne-in-laboratorio

#epatite #CRISPR

L'epatite E uccide ogni anno 44 mila persone nel mondo. Non esiste un farmaco specifico: vent'anni di ricerca, e ancora terapia di supporto. Ora un gruppo della Ruhr-Universität di Bochum ha mostrato che il sistema CRISPR/Cas13d, quello che taglia l'RNA invece del DNA, riesce a spegnere il virus nelle cellule umane.

È una fase di laboratorio, capiamoci: non ancora un farmaco. Ma di novità serie su questo virus se ne vedono poche. Benvenuta ricerca.

https://www.futuroprossimo.it/2026/05/epatite-e-nel-mirino-di-crispr-il-virus-si-spegne-in-laboratorio

#epatite #CRISPR

Seul Ulusal Üniversitesi'nden bilim insanları, DNA'yı kesmeden çalışan yeni bir CRISPR sistemi geliştirdi. Genetiği değiştirilmiş bakterileri kalıcı olarak etkisiz hale getirebiliyor. Gen düzenlemede çığır açan bu adım!

🚩 #CRISPR #GenDuzenleme #Bilim #Teknoloji #Arastirma

Interesting new #CRISPR papers. Two studies show that Cas12a2 can act as a RNA-guided DNA shredder to selectively kill cancer cells. www.nature.com/articles/s41... www.biorxiv.org/content/10.6...

Interesting new #CRISPR papers. Two studies show that Cas12a2 can act as a RNA-guided DNA shredder to selectively kill cancer cells. www.nature.com/articles/s41... www.biorxiv.org/content/10.6...

Interesting new #CRISPR papers. Two studies show that Cas12a2 can act as a RNA-guided DNA shredder to selectively kill cancer cells. www.nature.com/articles/s41... www.biorxiv.org/content/10.6...

Interesting new #CRISPR papers. Two studies show that Cas12a2 can act as a RNA-guided DNA shredder to selectively kill cancer cells. www.nature.com/articles/s41... www.biorxiv.org/content/10.6...

Investigadores en Sudáfrica aplican tecnología de edición genética CRISPR para crear vides más resistentes https://www.vinetur.com/20260511100500/south-african-scientists-use-crispr-on-grapevines.html #CRISPR #Investigación #Genética #Vides #CambioClimático

Investigadores en Sudáfrica aplican tecnología de edición genética CRISPR para crear vides más resistentes https://www.vinetur.com/20260511100500/south-african-scientists-use-crispr-on-grapevines.html #CRISPR #Investigación #Genética #Vides #CambioClimático

Some gene therapies no longer require clinical trials, thanks to new FDA rule. Is this safe, and who will it help?. Via @live_science #Health ❤️‍🩹 🧑‍⚕️ #MedicalScience 💉💊🏥🩸😷 #Science #CRISPR 🔭🔬🧪🥼🧑‍🔬

Some gene therapies no longer ...

Some gene therapies no longer require clinical trials, thanks to new FDA rule. Is this safe, and who will it help?. Via @live_science #Health ❤️‍🩹 🧑‍⚕️ #MedicalScience 💉💊🏥🩸😷 #Science #CRISPR 🔭🔬🧪🥼🧑‍🔬

Some gene therapies no longer ...

Some gene therapies no longer require clinical trials, thanks to new FDA rule. Is this safe, and who will it help?. Via @live_science #Health ❤️‍🩹 🧑‍⚕️ #MedicalScience 💉💊🏥🩸😷 #Science #CRISPR 🔭🔬🧪🥼🧑‍🔬

Some gene therapies no longer ...

Some gene therapies no longer require clinical trials, thanks to new FDA rule. Is this safe, and who will it help?. Via @live_science #Health ❤️‍🩹 🧑‍⚕️ #MedicalScience 💉💊🏥🩸😷 #Science #CRISPR 🔭🔬🧪🥼🧑‍🔬

Some gene therapies no longer ...

Some gene therapies no longer require clinical trials, thanks to new FDA rule. Is this safe, and who will it help?. Via @live_science #Health ❤️‍🩹 🧑‍⚕️ #MedicalScience 💉💊🏥🩸😷 #Science #CRISPR 🔭🔬🧪🥼🧑‍🔬

Some gene therapies no longer ...

Myrabello heißt der erste in Europa „gecrisperte“ Weißbüschelaffe. Mit ihm entstand ein #Tiermodell, das die #Therapie menschlicher #Taubheit auf völlig neue Weise erforschbar macht. Petra Neis-Beeckmann erzählt seine Geschichte: https://www.laborjournal.de/editorials/3488.php #CRISPR #Geneediting

Myrabello heißt der erste in Europa „gecrisperte“ Weißbüschelaffe. Mit ihm entstand ein #Tiermodell, das die #Therapie menschlicher #Taubheit auf völlig neue Weise erforschbar macht. Petra Neis-Beeckmann erzählt seine Geschichte: https://www.laborjournal.de/editorials/3488.php #CRISPR #Geneediting

Myrabello heißt der erste in Europa „gecrisperte“ Weißbüschelaffe. Mit ihm entstand ein #Tiermodell, das die #Therapie menschlicher #Taubheit auf völlig neue Weise erforschbar macht. Petra Neis-Beeckmann erzählt seine Geschichte: https://www.laborjournal.de/editorials/3488.php #CRISPR #Geneediting

Myrabello heißt der erste in Europa „gecrisperte“ Weißbüschelaffe. Mit ihm entstand ein #Tiermodell, das die #Therapie menschlicher #Taubheit auf völlig neue Weise erforschbar macht. Petra Neis-Beeckmann erzählt seine Geschichte: https://www.laborjournal.de/editorials/3488.php #CRISPR #Geneediting

Myrabello heißt der erste in Europa „gecrisperte“ Weißbüschelaffe. Mit ihm entstand ein #Tiermodell, das die #Therapie menschlicher #Taubheit auf völlig neue Weise erforschbar macht. Petra Neis-Beeckmann erzählt seine Geschichte: https://www.laborjournal.de/editorials/3488.php #CRISPR #Geneediting

Target Enrichment Probes Market in Germany | Report – IndexBox

Germany Target Enri…
#Germany #DE #Europe #EU #Europa #Amplicon-basedEnrichment(competingtech) #biopharmamarketreport #CRISPR-basedgeneeditingandscreening #CRISPR-Cassystemdesign #forecast #HybridCapture(Solution-phase) #LiquidbiopsyandctDNAanalysis #marketanalysis #Phosphoramidite-basedOligoSynthesis #targetenrichmentprobes #Targetednext-generationsequencing(NGS) #Whole-exomesequencing(WES)
https://www.europesays.com/germany/11540/

Ionizable Lipids Market in Germany | Report – IndexBox

This report is an independent strategic market study that provides a structure…
#Germany #DE #Europe #EU #Europa #Analyticalcharacterization(HPLC #biopharmamarketreport #Chemicalsynthesis(multi-step) #CRISPR/Cassystemdelivery #forecast #Genetherapydelivery #Ionizablelipids #Lipidnanoparticleformulation #marketanalysis #mRNAvaccinedelivery #MS) #OncologyRNAtherapeutics #Processscale-upandpurification
https://www.europesays.com/germany/11464/

Cas9 Nuclease Market in Germany | Report – IndexBox

Germany Cas9 Nuclease Market 2026 Analy…
#Germany #DE #Europe #EU #Europa #biopharmamarketreport #CAR-T #Cas9nuclease #Creationofdiseasemodels #CRISPR-Cas9system #Engineeringofcelltherapies(e.g. #forecast #Formulationandstabilizationtechnologies #Functionalgenomicsscreens #Geneknockoutandknock-instudies #High-throughputeditingefficiencyassays #marketanalysis #Recombinantproteinexpressionandpurification
https://www.europesays.com/germany/11092/

Cas9 Nuclease Market in Spain | Report – IndexBox

Spain Cas9 Nuclease Market 2026 Analysis and…
#Spain #ES #Europe #Europa #EU #biopharmamarketreport #CAR-T) #Cas9nuclease #Creationofdiseasemodels #CRISPR-Cas9system #Engineeringofcelltherapies(e.g. #forecast #Formulationandstabilizationtechnologies #Functionalgenomicsscreens #Geneknockoutandknock-instudies #High-throughputeditingefficiencyassays #marketanalysis #Recombinantproteinexpressionandpurification
https://www.europesays.com/spain/19042/

Viele Anwendungen in der Medizin, der #Biotechnologie oder der Landwirtschaft erfordern die gezielte Abtötung unerwünschter Zellen. Dabei kann es sich bspw. um Zellen handeln, die die Gesundheit gefährden, die Produktivität beeinträchtigen od. gewünschte biologische Prozesse stören. Forscher:innen des @Helmholtz_HIRI entwickelten nun gemeinsam mit Kooperationspartnern ein #CRISPR-basiertes Werkzeug, das Zellen gezielt beseitigen kann.
📷Liu Lab / University of Utah Health
https://www.helmholtz-hzi.de/media-center/newsroom/news-detailseite/wie-ein-molekulares-skalpell-neues-crispr-werkzeug-beseitigt-unerwuenschte-zellen-im-handumdrehen/

Viele Anwendungen in der Medizin, der #Biotechnologie oder der Landwirtschaft erfordern die gezielte Abtötung unerwünschter Zellen. Dabei kann es sich bspw. um Zellen handeln, die die Gesundheit gefährden, die Produktivität beeinträchtigen od. gewünschte biologische Prozesse stören. Forscher:innen des @Helmholtz_HIRI entwickelten nun gemeinsam mit Kooperationspartnern ein #CRISPR-basiertes Werkzeug, das Zellen gezielt beseitigen kann.
📷Liu Lab / University of Utah Health
https://www.helmholtz-hzi.de/media-center/newsroom/news-detailseite/wie-ein-molekulares-skalpell-neues-crispr-werkzeug-beseitigt-unerwuenschte-zellen-im-handumdrehen/

Viele Anwendungen in der Medizin, der #Biotechnologie oder der Landwirtschaft erfordern die gezielte Abtötung unerwünschter Zellen. Dabei kann es sich bspw. um Zellen handeln, die die Gesundheit gefährden, die Produktivität beeinträchtigen od. gewünschte biologische Prozesse stören. Forscher:innen des @Helmholtz_HIRI entwickelten nun gemeinsam mit Kooperationspartnern ein #CRISPR-basiertes Werkzeug, das Zellen gezielt beseitigen kann.
📷Liu Lab / University of Utah Health
https://www.helmholtz-hzi.de/media-center/newsroom/news-detailseite/wie-ein-molekulares-skalpell-neues-crispr-werkzeug-beseitigt-unerwuenschte-zellen-im-handumdrehen/

Viele Anwendungen in der Medizin, der #Biotechnologie oder der Landwirtschaft erfordern die gezielte Abtötung unerwünschter Zellen. Dabei kann es sich bspw. um Zellen handeln, die die Gesundheit gefährden, die Produktivität beeinträchtigen od. gewünschte biologische Prozesse stören. Forscher:innen des @Helmholtz_HIRI entwickelten nun gemeinsam mit Kooperationspartnern ein #CRISPR-basiertes Werkzeug, das Zellen gezielt beseitigen kann.
📷Liu Lab / University of Utah Health
https://www.helmholtz-hzi.de/media-center/newsroom/news-detailseite/wie-ein-molekulares-skalpell-neues-crispr-werkzeug-beseitigt-unerwuenschte-zellen-im-handumdrehen/

Viele Anwendungen in der Medizin, der #Biotechnologie oder der Landwirtschaft erfordern die gezielte Abtötung unerwünschter Zellen. Dabei kann es sich bspw. um Zellen handeln, die die Gesundheit gefährden, die Produktivität beeinträchtigen od. gewünschte biologische Prozesse stören. Forscher:innen des @Helmholtz_HIRI entwickelten nun gemeinsam mit Kooperationspartnern ein #CRISPR-basiertes Werkzeug, das Zellen gezielt beseitigen kann.
📷Liu Lab / University of Utah Health
https://www.helmholtz-hzi.de/media-center/newsroom/news-detailseite/wie-ein-molekulares-skalpell-neues-crispr-werkzeug-beseitigt-unerwuenschte-zellen-im-handumdrehen/

https://www.europesays.com/es/537758/ este nuevo CRISPR «aniquila» el cáncer #aniquila #bisturi #cáncer #células #crispr #ES #España #genético #Health #nuevo #Salud #Spain #trituradora

A novel #CRISPR/Cas based method selectively eliminates mutant cells expressing a target transcript through RNA-triggered DNA shredding. Robust in vitro performance, but in vivo cellular delivery remains the major hurdle.

#science

https://www.nature.com/articles/s41586-026-10466-y

A novel #CRISPR/Cas based method selectively eliminates mutant cells expressing a target transcript through RNA-triggered DNA shredding. Robust in vitro performance, but in vivo cellular delivery remains the major hurdle.

#science

https://www.nature.com/articles/s41586-026-10466-y